Picture: BioSenic

BioSenic strengthens scientific team with new CSO

Dr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic's cell therapy and autoimmune disease platform pipeline and be responsible for R&D programmes.

Dr Carole Nicco will be responsible for BioSenic's scientific research and development. Nicco has more than two decades of experience in cancer biology and immunology, inflammation, immunity, novel target identification and drug discovery. Prior to joining BioSenic, she actively led programmes from discovery to preclinical studies in collaboration with renowned pharmaceutical companies (Vertex, BOIRON, IPRAD/GYNOV, Medsenic). She has also led dozens of preclinical studies in diseases ranging from cancer to endometriosis, as well as autoimmune diseases (SLE, SSc, cGVHD) or diseases in which the immune system plays a role, such as wound healing, uveitis, sepsis, hepatitis and endometriosis.

From 2005 to 2023, Carole was one of the principal investigators and laboratory manager of the research team "Pathogenesis and innovative treatments for chronic fibro-inflammatory diseases" at the Institut Cochin, a biomedical research centre affiliated to INSERM (Unit 1016), CNRS (UMR 8104) and Paris Cité University. For the last 10 years, she has also been head of the conventional preclinical structure of the Cochin Institute.

Since 2016, Dr Nicco has been a member of the scientific committee and advisory board of four international congresses: Paris Redox, Targeting Mitochondria, Targeting Microbiota and Skin Challenges. In 2023, Dr Nicco will become President of the international non-profit organisation Redox Medicine Society (formerly the International Society of Antioxidants in Nutrition and Health). She is the author of 110 articles published in international journals on autoimmune diseases, inflammation and cancer. Dr Nicco holds a PhD in Human Physiology and Physiopathology from Denis Diderot University in Paris, France.